Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2

IV infusion Day 1 every 21 days, at dose of 200 mg

IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2

IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)